FDA announced FY2018 rates for the establishment and re-inspection fees related to entities that compound human drugs and elect to register as outsourcing facilities. The document establishes the FY 2018 fees for: • the small business establishment fee ($5,364), • the non-small business establishment fee ($17,364), and • the re-inspection fee ($16,093) for outsourcing facilities. Also provided is information on how the fees for FY 2018 were determined and the payment procedures outsourcing facilities should follow. The new rates were effective October 1, 2017, and will remain in effect through September 30, 2018.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
